Payment overview · 2025
General Payments
$380.19
22 reported records · 11 companies
Healthcare provider profile · identity verified
Robert P Hogan, D.O. P.C.
Allopathic & Osteopathic Physicians|Internal Medicine · EWING, NJ · NPI 1396708632
Verified facts
What the public records show
CMS Open Payments records show Robert P Hogan, D.O. P.C. received $380.19 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.26 | 21.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.92 | 15.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.95 | 13.7% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $38.92 | 10.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.48 | 9.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.45 | 7.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.50 | 6.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $18.33 | 4.8% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.74 | 3.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.70 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.19 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.92 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.95 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.02 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 447 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 81 |
| Alprazolam | Alprazolam | 220 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 44 |
| Losartan Potassium | Losartan Potassium | 163 | 46 |
| Lisinopril | Lisinopril | 152 | 41 |
| Metformin Hcl | Metformin Hcl | 132 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 41 |
| Gabapentin | Gabapentin | 115 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 63 |
| Omeprazole | Omeprazole | 98 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 30 |
| Montelukast Sodium | Montelukast Sodium | 84 | 33 |
| Carvedilol | Carvedilol | 83 | 26 |
| Furosemide | Furosemide | 81 | 29 |
| Ezetimibe | Ezetimibe | 80 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 24 |
| Metformin Hcl Er | Metformin Hcl | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 78 | 26 |
| Glimepiride | Glimepiride | 77 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 24 |
| Januvia | Sitagliptin Phosphate | 74 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 23 |
| Telmisartan | Telmisartan | 71 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 19 |
| Potassium Chloride | Potassium Chloride | 62 | 12 |
| Eliquis | Apixaban | 61 | 18 |
| Allopurinol | Allopurinol | 60 | 19 |
| Ibuprofen | Ibuprofen | 57 | 18 |
| Simvastatin | Simvastatin | 57 | 15 |
| Meloxicam | Meloxicam | 56 | 15 |
| Mupirocin | Mupirocin | 56 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Naproxen | Naproxen | 51 | 11 |
| Lorazepam | Lorazepam | 48 | 12 |
| Celecoxib | Celecoxib | 47 | 12 |
| Desloratadine | Desloratadine | 44 | 14 |
| Clonazepam | Clonazepam | 43 | 16 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Nifedipine Er | Nifedipine | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | 11 |
| Azithromycin | Azithromycin | 38 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Valsartan | Valsartan | 34 | 15 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Invokana | Canagliflozin | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Linzess | Linaclotide | 26 | 13 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Prednisone | Prednisone | 23 | 19 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 12 |
| Paroxetine Cr | Paroxetine Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 15 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.19 · 22 records | Novo Nordisk Inc | ABRYSVO, BEXSERO, COMIRNATY, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, LUMRYZ, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, WAKIX, Wegovy, XYWAV, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error